• Title/Summary/Keyword: Jolkinolide B

Search Result 1, Processing Time 0.014 seconds

Jolkinolide B Ameliorates Liver Inflammation and Lipogenesis by Regulating JAK/STAT3 Pathway

  • Hye-Rin Noh;Guoyan Sui;Jin Woo Lee;Feng Wang;Jeong-Su Park;Yuanqiang Ma;Hwan Ma;Ji-Won Jeong;Dong-Su Shin;Xuefeng Wu;Bang-Yeon Hwang;Yoon Seok Roh
    • Biomolecules & Therapeutics
    • /
    • v.32 no.6
    • /
    • pp.793-800
    • /
    • 2024
  • Hepatic dysregulation of lipid metabolism exacerbates inflammation and enhances the progression of metabolic dysfunction-associated steatotic liver disease (MASLD). STAT3 has been linked to lipid metabolism and inflammation. Jolkinolide B (JB), derived from Euphorbia fischeriana, is known for its pharmacological anti-inflammatory and anti-tumor properties. Therefore, this study investigated whether JB affects MASLD prevention by regulating STAT3 signaling. JB attenuated steatosis and inflammatory responses in palmitic acid (PA)-treated hepatocytes. Additionally, JB treatment reduced the mRNA expression of de-novo lipogenic genes, such as acetyl-CoA carboxylase and stearoyl-CoA desaturase 1. Interestingly, JB-mediated reduction in inflammation and lipogenesis was dependent on STAT3 signaling. JB consistently modulated mitochondrial dysfunction and the mRNA expression of inflammatory cytokines by inhibiting PA-induced JAK/STAT3 activation. This study suggests that JB is a potential therapeutic agent to prevent major stages of MASLD through inhibition of JAK/STAT3 signaling in hepatocytes.